OptimiTM-03.jpg
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
29 mai 2024 08h00 HE | Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
OptimiTM-03.jpg
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
14 mai 2024 08h00 HE | Optimi Health Corp.
Optimi Health Receives Certificate of Analysis For GMP MDMA 40mg and 60mg MDMA Capsules.
OptimiTM-03.jpg
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE | Optimi Health Corp.
Optimi Health provides corporate update.
OptimiTM-03.jpg
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
09 mai 2024 08h00 HE | Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export
OptimiTM-03.jpg
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research
23 avr. 2024 08h18 HE | Optimi Health Corp.
Optimi Health announces innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre.
OptimiTM-03.jpg
Optimi Health Signs Psilocybin Supply Agreement With New Zealand-Based Mātai Medical Research Institute
09 avr. 2024 09h13 HE | Optimi Health Corp.
Optimi signs international natural psilocybin supply agreement with New Zealand-Based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.
OptimiTM-03.jpg
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
02 avr. 2024 07h30 HE | Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
OptimiTM-03.jpg
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
28 mars 2024 07h30 HE | Optimi Health Corp.
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
OptimiTM-03.jpg
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
26 mars 2024 07h30 HE | Optimi Health Corp.
Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel
JJ Wilson
Optimi Announces Closing of First Tranche of Non-Brokered Private Placement
28 févr. 2024 07h30 HE | Optimi Health Corp.
VANCOUVER, British Columbia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Health Canada licensed drug researcher and...